Teva, Biolojic Design initiate IND-enabling studies of BD9

Teva (TEVA) Pharmaceutical and Biolojic Design announced that Teva initiated IND-enabling studies with BD9, a dual-specific multibody targeting both TSLP and IL-13. Teva has an exclusive license to develop BD9 for the treatment of TH2-driven inflammatory diseases such as atopic dermatitis and asthma. Teva’s development of BD9 demonstrates the company’s commitment to applying cutting-edge science to address unmet medical needs. By simultaneously blocking two key drivers of TH2-driven inflammation, BD9 has the potential to improve outcomes for patients with conditions such as atopic dermatitis and asthma, where current treatments fall short. The initiation of IND-enabling studies marks a critical milestone in translating this scientific innovation into a potential therapeutic option, paving the way for clinical trials and ultimately bringing hope to underserved patient populations. This progress exemplifies Teva’s focus on advancing transformative therapies that expand access and impact through innovation.